Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...
The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback